Idera Pharmaceuticals acquires rare orphan disease company Aceragen

Idera Pharmaceuticals, a US-based biopharma company, has acquired Aceragen, a biotechnology company focused on developing drugs for rare, orphan pulmonary,  and rheumatic diseases. The acquisition ... Read More